Understanding Bipolar Disorder: Symptoms, Brain Science, Treatment, Recovery and Hope

Bipolar disorder is treatable, and stability, purpose, relationships and professional success remain realistic goals.

Bipolar disorder is more than ordinary moodiness

Bipolar disorder is a group of episodic mood conditions that can substantially change mood, energy, sleep, activity, judgment and daily functioning. It is not a character flaw, a lack of faith, "split personality," or the ordinary emotional variation everyone experiences. During an episode, the change is sustained, differs from the person's usual baseline, and may produce serious consequences. Yet bipolar disorder is also treatable. With accurate diagnosis, medication, psychotherapy, stable sleep, healthy routines and supportive relationships, many people build successful careers and meaningful family lives.

Bipolar I disorder requires at least one manic episode. Major depressive episodes are common but are not required for the diagnosis. Bipolar II disorder involves at least one hypomanic episode and at least one major depressive episode, without a history of full mania. Cyclothymic disorder involves chronic fluctuations between subthreshold hypomanic and depressive symptoms. Mixed features describe episodes in which symptoms from both mood poles occur together.

Recognizing mania and hypomania

Mania is an abnormally elevated, expansive or persistently irritable mood accompanied by increased energy or activity. It lasts at least one week for most diagnoses, or any duration when hospitalization is required. It causes marked impairment and may include psychosis. Hypomania involves a similar change lasting at least four consecutive days, but it does not cause marked impairment, hospitalization or psychosis.

• Needing very little sleep without feeling tired
• Talking much more or faster than usual
• Racing thoughts or rapidly shifting ideas
• Unusual confidence, grandiosity or feeling specially gifted
• Marked distractibility
• Increased productivity, projects, social activity or agitation
• Impulsive spending, gambling, sexual risk-taking, reckless driving or abrupt business decisions
• Irritability, confrontation, aggression or inability to slow down
• Psychotic beliefs or hallucinations during severe mania

Irritable mania is common; a person does not have to appear cheerful or euphoric. Decreased need for sleep is especially important: the person may sleep only a few hours and still feel energized, which differs from insomnia accompanied by fatigue.

Recognizing bipolar depression

• Persistent sadness, emptiness or irritability
• Loss of interest or pleasure
• Fatigue and reduced motivation
• Sleeping excessively or being unable to sleep
• Appetite or weight changes
• Slowed movement or agitation
• Poor concentration and indecision
• Excessive guilt, hopelessness or worthlessness
• Withdrawal from work, family or friends
• Thoughts of death, self-harm or suicide

Depression often accounts for more cumulative suffering and disability than mania. Mixed episodes can be particularly dangerous because painful depressive thinking may coexist with agitation, energy, impulsivity and reduced sleep.

Screening questionnaire: bipolar spectrum

The questionnaire below is an original educational screening tool, not a validated diagnostic instrument. Your answers are scored only in your browser; nothing is saved or transmitted. A positive result means a professional evaluation may be appropriate — it does not mean you have bipolar disorder.

After you finish the questionnaire, you can see your full result and next steps on a dedicated page.

Can someone control their actions during mania?

Control may be significantly impaired, but it is not automatically or completely absent. Mania can weaken insight, inhibitory control, risk evaluation, appreciation of consequences and reality testing. A person may genuinely believe a dangerous decision is sensible or urgently necessary. Severe mania with psychosis can profoundly disrupt decision-making. Still, a diagnosis alone does not establish that someone lacked all capacity, intent, control or legal responsibility. Those questions require an individualized clinical or forensic evaluation of the person's symptoms and abilities at the relevant time.

What happens in the brain

Bipolar disorder does not arise from one chemical imbalance or one damaged brain area. Current research describes a network-level disorder involving genetic vulnerability, circadian rhythms, cellular energy, neuroplasticity, neurotransmission, inflammation, and communication among brain regions that regulate reward, emotion, attention and inhibition.

During mania

Research suggests increased reward sensitivity and salience, altered dopamine signaling, disrupted glutamate and GABA balance, disturbed sleep and circadian regulation, and reduced top-down regulation by prefrontal systems over limbic and reward circuits. These changes may contribute to accelerated thinking, grandiosity, risk-taking, distractibility, irritability and impaired consequence evaluation.

In plain language, "top-down regulation" is the brain's braking and steering system. Prefrontal regions normally help pause an impulse, compare a choice with long-term goals, reinterpret emotionally charged information, and dampen signals from reward and threat circuits. During mania, this regulatory influence may become less effective while limbic and reward networks become unusually active. The result can be faster decisions, greater confidence, stronger pursuit of rewards, reduced appreciation of risk, and difficulty slowing behavior even when others identify consequences. This is a group-level neurobiological model, not a brain scan test for an individual patient.

During depression

Bipolar depression is associated with reduced reward responsiveness, altered prefrontal-limbic connectivity, impaired motivation, psychomotor changes, and abnormalities involving stress-response, inflammatory, mitochondrial and neuroplasticity pathways. These are group-level findings and cannot currently diagnose an individual through a routine brain scan.

What people mean by "bipolar eyes"

"Bipolar eyes" is an informal internet phrase, not a medical diagnosis or established physical sign. During mania or intense agitation, a person may appear to have a more fixed or intense gaze, widened eyelids, less blinking, or larger pupils. Those changes can reflect arousal, sleep loss, lighting, medication effects, substance use, anxiety or sympathetic nervous-system activation; they are not specific to bipolar disorder. During depression, reduced eye contact or a less animated expression may occur, but these findings are also nonspecific. Researchers are studying pupil responses and retinal imaging as possible group-level biomarkers. Current evidence is preliminary and cannot determine from someone's eyes whether that person has bipolar disorder, is manic, or needs a particular treatment.

Causes and usual age of onset

No single cause explains bipolar disorder. It is strongly heritable and polygenic: many genetic variations contribute small amounts of risk. Sleep loss, trauma, psychosocial stress, substances, postpartum changes, medical conditions and certain medications can precipitate an episode in a vulnerable person, but none alone explains every case. Symptoms often begin in late adolescence or early adulthood, with an average onset near age 25. Diagnosis may be delayed because people often seek care for depression and may view hypomania as productivity rather than illness.

Which genes are involved

No single "bipolar gene" is responsible. Bipolar disorder is highly polygenic: thousands of common variants, each with a very small effect, combine with rarer variants and environmental exposures. The largest multi-ancestry genome-wide study to date identified 298 associated genomic regions and implicated 36 genes through converging analyses. Frequently discussed signals include CACNA1C and other voltage-gated calcium-channel genes, ANK3, TRANK1, ODZ4/TENM4, NCAN, and genes involved in synaptic signaling, neuronal excitability, circadian biology and neurotransmitter pathways. These associations describe population risk, not destiny. A person can carry risk variants and never develop bipolar disorder, and routine genetic testing cannot currently confirm or exclude the diagnosis. Family history remains clinically more useful than a consumer DNA result.

Who is affected

Bipolar disorder occurs across sexes, racial and ethnic groups, cultures and countries. Bipolar I prevalence is broadly similar in men and women, although women may experience more depressive burden or rapid cycling in some samples, while men often show more substance-use comorbidity and higher suicide mortality. Apparent racial differences in diagnosis may reflect access, culture, clinician bias and misclassification. International rankings must also be interpreted cautiously because detection and data quality vary.

Intelligence, careers and disability

Bipolar disorder does not determine intelligence. People with the condition represent the full intellectual spectrum. Some experience attention, processing-speed, memory or executive-function difficulties, particularly during episodes or after recurrent severe illness. Others retain excellent cognitive and occupational functioning. Creativity and achievement have been associated with some bipolar traits, but illness should not be romanticized as the source of genius.

Many people with bipolar disorder become successful clinicians, business owners, attorneys, educators, scientists, artists and leaders. Outcomes depend on episode severity, duration of untreated illness, sleep, treatment response, substance use, cognitive symptoms, workplace support and access to care. There is no scientifically defensible universal percentage of patients who are "completely disabled." Functional impact ranges from little lasting limitation to temporary leave, partial impairment, recurrent disability, or inability to sustain employment.

Family life and the importance of support

Many people with bipolar disorder maintain loving marriages, raise children and build stable homes. Untreated episodes can nevertheless strain trust through spending, irritability, infidelity, withdrawal, disrupted parenting, substance use or abrupt life decisions. Recovery may require treatment, financial safeguards, respectful boundaries, family education and time to rebuild trust.

Supportive relatives and friends can notice early changes in sleep, speech, spending, energy or irritability; encourage treatment; help protect medication and sleep routines; support transportation or childcare; and participate in safety planning. Support does not require tolerating dangerous behavior. Family-focused therapy and psychoeducation can help relatives respond effectively while maintaining clear boundaries.

Common comorbidities and physical health

Common psychiatric comorbidities include anxiety disorders, substance-use disorders, ADHD, PTSD, personality disorders, eating disorders and obsessive-compulsive symptoms. The CANMAT/ISBD update reports substance-use disorders in roughly one-third of community samples and about 45 percent of clinical samples, anxiety disorders in approximately 24 to 56 percent, ADHD in approximately 10 to 20 percent, and personality disorders in some samples around 42 percent. Medical concerns include obesity, metabolic syndrome, diabetes, cardiovascular disease, migraine, sleep disorders, and thyroid, renal or endocrine complications.

Life expectancy and suicide risk

On average, bipolar disorder is associated with shortened life expectancy, often estimated at roughly 8 to 12 years, although estimates differ. Cardiovascular disease, diabetes, smoking, obesity, substance use, reduced preventive care, accidents and suicide all contribute. Much of this risk can be reduced through psychiatric stability, primary care, metabolic monitoring, exercise, smoking cessation and substance-use treatment.

Bipolar disorder carries one of the highest suicide risks among psychiatric illnesses. Risk is especially elevated during depressive or mixed episodes, after hospitalization, following a previous attempt, and when substance use, severe anxiety, interpersonal loss, financial crisis or access to lethal means is present. Suicide risk should be assessed directly and repeatedly. Lithium has among the strongest evidence for reducing suicide-related outcomes, although treatment must be individualized and monitored.

Misunderstandings that increase stigma

• Bipolar disorder is not ordinary moodiness or a "split personality."
• Most patients are not violent; risk is shaped more by active symptoms, substances, history and circumstances than by a diagnostic label.
• A manic act may reflect impaired judgment, but diagnosis alone does not answer legal or moral responsibility.
• People with bipolar disorder are not inherently unreliable, unintelligent, unfit to parent or unable to lead.
• Medication is not a punishment or proof of weakness; it is one component of relapse prevention.
• Spiritual support may be valuable, but bipolar disorder is not evidence of deficient faith or personal sin.

Historical public figures and diagnostic caution

Virginia Woolf, Ernest Hemingway, Sylvia Plath and Vincent van Gogh are frequently discussed as possibly having had bipolar-spectrum illness, and each died by suicide. Margot Kidder publicly described having bipolar disorder and died by suicide in 2018. Retrospective diagnosis is uncertain, particularly when several explanations have been proposed. Their lives should not be used to imply that creativity causes bipolar disorder or that suicide is inevitable. Rather, their stories show both human accomplishment and the seriousness of mood illness.

Gold standard treatment

Treatment is phase-specific and individualized. The strongest care model combines mood-stabilizing medication, psychoeducation, consistent sleep, avoidance of destabilizing substances, medical monitoring, suicide prevention and psychotherapy. Evidence supports psychoeducation, cognitive behavioral therapy, family-focused therapy, and interpersonal and social rhythm therapy as adjuncts. Most people with Bipolar I disorder need maintenance treatment after an acute episode.

Acute mania. Evidence-supported options include lithium, divalproex, quetiapine, aripiprazole, risperidone, asenapine, cariprazine and paliperidone; severe episodes may require a mood stabilizer plus an antipsychotic. Clinicians stop destabilizing antidepressants when clinically appropriate and assess psychosis, safety, adherence, substances, sleep, pregnancy potential and the need for hospitalization.

Bipolar depression. Evidence-supported options include quetiapine, lurasidone, cariprazine, lumateperone, lithium, lamotrigine, olanzapine-fluoxetine and selected use of divalproex. ECT may be appropriate for severe, psychotic, catatonic, suicidal or resistant depression. Antidepressant monotherapy is not recommended for Bipolar I depression, and clinicians watch for switching, mixed symptoms and rapid cycling.

Maintenance. Options include lithium, quetiapine, divalproex, lamotrigine, asenapine, aripiprazole and selected combinations based on polarity and prior response, with monitoring of metabolic health, renal and thyroid function when relevant, adverse effects, interactions, adherence and pregnancy-related risks.

This information is educational. Do not start, stop or change any medication without speaking with your prescriber.

How lithium works

Lithium does not work through one receptor. As a small ion, it enters neurons and changes several intracellular signaling systems. At therapeutic concentrations it inhibits enzymes including glycogen synthase kinase-3 (GSK-3) and inositol monophosphatase, which influences second-messenger signaling, gene expression, circadian timing, synaptic plasticity, inflammation and cellular resilience. Over time, lithium may strengthen neuroprotective pathways, stabilize communication among dopamine, glutamate, GABA and serotonin systems, and reduce abnormal swings in network excitability. Its clinical effects develop gradually. Lithium has strong evidence for preventing manic and depressive relapse and is associated with reduced suicide risk, but it requires individualized dosing and monitoring of blood levels, kidney function, thyroid function, calcium, hydration, interactions, pregnancy considerations and toxicity symptoms.

What future bipolar treatment research may bring

A 2025 review of emerging bipolar pharmacotherapy describes a shift from trial-and-error prescribing toward precision psychiatry. Research directions include using clinical course, genetics, sleep and circadian patterns, immune-metabolic markers, neuroimaging and digital monitoring to match treatments more precisely. Investigational targets include glutamate and NMDA signaling, inflammation, oxidative stress, mitochondrial function, neurosteroids, phosphodiesterase pathways, neuropeptides and metabolic signaling. Ketamine-like approaches, anti-inflammatory strategies, GLP-1 receptor agonists for metabolic and possibly mood-related pathways, and individualized chronotherapy are being studied, but most are not established replacements for standard mood stabilizers. Better lithium monitoring, including minimally invasive or saliva-based sensing, may also improve safety. These developments are promising, yet biomarkers still require validation and emerging therapies need well-powered bipolar-specific trials before routine clinical use.

Clinical pearls for patients and families

• Ask about lifetime mania or hypomania before treating recurrent depression.
• Track sleep, because reduced need for sleep can be an early warning sign and a trigger.
• Collect collateral history when permitted; insight and recall can change during episodes.
• Treat screening questionnaires as prompts for evaluation, not diagnoses.
• Create a written relapse plan during stability, including early signs, preferred contacts, medication steps and emergency thresholds.
• Use financial protections during high-risk periods, such as spending limits or temporary shared oversight.
• Address side effects openly; tolerability is central to long-term adherence.
• Treat substance use and physical health as part of bipolar care, not as separate problems.

Prognosis and hope

Bipolar disorder is usually a lifelong vulnerability, but it is not a life sentence of continuous instability. Many people experience prolonged remission and maintain careers, relationships, parenting roles, faith, creativity and community leadership. Earlier diagnosis, fewer untreated episodes, consistent treatment, stable sleep, avoidance of substances, strong support, and early intervention when warning signs return are associated with better outcomes.

How Turned Leaf Psychiatry can help

Turned Leaf Psychiatry provides individualized psychiatric evaluation and treatment planning for people experiencing possible mania, hypomania, depression, mixed symptoms, sleep disruption, impulsivity or recurrent mood instability. Evaluation may include a detailed longitudinal history, medication and substance review, family history, validated screening tools, medical differential diagnosis, collateral information when appropriate, and assessment of safety and functioning.

Treatment may include evidence-based medication management, pharmacogenomic testing when clinically useful, psychotherapy coordination, education for patients and families, relapse-prevention planning and ongoing monitoring. Care is designed to be evidence-based, Christian centered and integrated while respecting each patient's individual beliefs, values and treatment preferences.

Request an appointment: Turned Leaf Psychiatry appointment page

Call: 601-494-5503

If symptoms involve immediate danger, inability to care for basic needs, psychosis, severe agitation or thoughts of suicide, call 911 or go to the nearest emergency department. In the United States, call or text 988 for the Suicide and Crisis Lifeline.

A diagnosis can name real suffering, but it does not define the whole person.